Compare III & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | III | BNR |
|---|---|---|
| Founded | 2006 | 2014 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Professional Services | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 251.4M | 216.9M |
| IPO Year | 2007 | 2020 |
| Metric | III | BNR |
|---|---|---|
| Price | $5.07 | $30.00 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $7.00 | N/A |
| AVG Volume (30 Days) | ★ 280.5K | 25.8K |
| Earning Date | 03-05-2026 | 03-24-2026 |
| Dividend Yield | ★ 3.53% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.19 | N/A |
| Revenue | ★ $241,289,000.00 | $75,749,382.00 |
| Revenue This Year | N/A | $136.32 |
| Revenue Next Year | $3.63 | N/A |
| P/E Ratio | $26.80 | ★ N/A |
| Revenue Growth | N/A | ★ 5.56 |
| 52 Week Low | $2.95 | $2.18 |
| 52 Week High | $6.45 | $41.72 |
| Indicator | III | BNR |
|---|---|---|
| Relative Strength Index (RSI) | 35.92 | 49.47 |
| Support Level | $5.06 | $29.50 |
| Resistance Level | $5.84 | $41.09 |
| Average True Range (ATR) | 0.19 | 3.75 |
| MACD | -0.07 | -0.93 |
| Stochastic Oscillator | 14.29 | 1.35 |
Information Services Group Inc is a U.S.-based technology insight, market intelligence, and advisory services firm. It principally offers digital transformation services, such as automation and cloud & data analytics; managed governance; network carrier services; technology plan and operations design; changes management; market intelligence & technology research and analysis. It operates in one segment, fact-based sourcing advisory services. Its geographical segments are the Americas, Europe, and Asia-pacific, out of which maximum revenue is derived from Americas.
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.